TOP2A and triple-negative breast carcinoma: TOP2A encodes topoisomerase (DNA) II alpha, somatic mutations in a TOP2A immunohistochemical score may be important in predicting response to immunotherapy treatment for triple-negative breast cancer (Jiang et al., 2021).